The global Tumor-on-a-chip market was valued at US$ 13 million in 2022 and is anticipated to reach US$ 69 million by 2029, witnessing a CAGR of 32.2% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Tumor-on-a-chip is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Tumor-on-a-chip is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Tumor-on-a-chip in Pharmaceutical & Biotechnology Companies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Tumor-on-a-chip include Cellesce, Daxiang Biotech, Mimetas, InSphero, Hepregen and Charles River, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor-on-a-chip, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor-on-a-chip.
The Tumor-on-a-chip market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Tumor-on-a-chip market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor-on-a-chip companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Cellesce
Daxiang Biotech
Mimetas
InSphero
Hepregen
Charles River
Segment by Type
PDX Model
CDX Model
Segment by Application
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor-on-a-chip companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Tumor-on-a-chip 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 PDX Model
1.2.3 CDX Model
1.3 麻豆原创 by Application
1.3.1 Global Tumor-on-a-chip 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical & Biotechnology Companies
1.3.3 Academic & Research Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor-on-a-chip 麻豆原创 Perspective (2018-2029)
2.2 Tumor-on-a-chip Growth Trends by Region
2.2.1 Global Tumor-on-a-chip 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tumor-on-a-chip Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Tumor-on-a-chip Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Tumor-on-a-chip 麻豆原创 Dynamics
2.3.1 Tumor-on-a-chip Industry Trends
2.3.2 Tumor-on-a-chip 麻豆原创 Drivers
2.3.3 Tumor-on-a-chip 麻豆原创 Challenges
2.3.4 Tumor-on-a-chip 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor-on-a-chip Players by Revenue
3.1.1 Global Top Tumor-on-a-chip Players by Revenue (2018-2023)
3.1.2 Global Tumor-on-a-chip Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Tumor-on-a-chip 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor-on-a-chip Revenue
3.4 Global Tumor-on-a-chip 麻豆原创 Concentration Ratio
3.4.1 Global Tumor-on-a-chip 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor-on-a-chip Revenue in 2022
3.5 Tumor-on-a-chip Key Players Head office and Area Served
3.6 Key Players Tumor-on-a-chip Product Solution and Service
3.7 Date of Enter into Tumor-on-a-chip 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor-on-a-chip Breakdown Data by Type
4.1 Global Tumor-on-a-chip Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Tumor-on-a-chip Forecasted 麻豆原创 Size by Type (2024-2029)
5 Tumor-on-a-chip Breakdown Data by Application
5.1 Global Tumor-on-a-chip Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Tumor-on-a-chip Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Tumor-on-a-chip 麻豆原创 Size (2018-2029)
6.2 North America Tumor-on-a-chip 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tumor-on-a-chip 麻豆原创 Size by Country (2018-2023)
6.4 North America Tumor-on-a-chip 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor-on-a-chip 麻豆原创 Size (2018-2029)
7.2 Europe Tumor-on-a-chip 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tumor-on-a-chip 麻豆原创 Size by Country (2018-2023)
7.4 Europe Tumor-on-a-chip 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor-on-a-chip 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Tumor-on-a-chip 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tumor-on-a-chip 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Tumor-on-a-chip 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor-on-a-chip 麻豆原创 Size (2018-2029)
9.2 Latin America Tumor-on-a-chip 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tumor-on-a-chip 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Tumor-on-a-chip 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor-on-a-chip 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Tumor-on-a-chip 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tumor-on-a-chip 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Tumor-on-a-chip 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cellesce
11.1.1 Cellesce Company Detail
11.1.2 Cellesce Business Overview
11.1.3 Cellesce Tumor-on-a-chip Introduction
11.1.4 Cellesce Revenue in Tumor-on-a-chip Business (2018-2023)
11.1.5 Cellesce Recent Development
11.2 Daxiang Biotech
11.2.1 Daxiang Biotech Company Detail
11.2.2 Daxiang Biotech Business Overview
11.2.3 Daxiang Biotech Tumor-on-a-chip Introduction
11.2.4 Daxiang Biotech Revenue in Tumor-on-a-chip Business (2018-2023)
11.2.5 Daxiang Biotech Recent Development
11.3 Mimetas
11.3.1 Mimetas Company Detail
11.3.2 Mimetas Business Overview
11.3.3 Mimetas Tumor-on-a-chip Introduction
11.3.4 Mimetas Revenue in Tumor-on-a-chip Business (2018-2023)
11.3.5 Mimetas Recent Development
11.4 InSphero
11.4.1 InSphero Company Detail
11.4.2 InSphero Business Overview
11.4.3 InSphero Tumor-on-a-chip Introduction
11.4.4 InSphero Revenue in Tumor-on-a-chip Business (2018-2023)
11.4.5 InSphero Recent Development
11.5 Hepregen
11.5.1 Hepregen Company Detail
11.5.2 Hepregen Business Overview
11.5.3 Hepregen Tumor-on-a-chip Introduction
11.5.4 Hepregen Revenue in Tumor-on-a-chip Business (2018-2023)
11.5.5 Hepregen Recent Development
11.6 Charles River
11.6.1 Charles River Company Detail
11.6.2 Charles River Business Overview
11.6.3 Charles River Tumor-on-a-chip Introduction
11.6.4 Charles River Revenue in Tumor-on-a-chip Business (2018-2023)
11.6.5 Charles River Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Cellesce
Daxiang Biotech
Mimetas
InSphero
Hepregen
Charles River
听
听
*If Applicable.
